Life science research has always been a difficult field. From basic cell culture to advanced clinical studies, much of the work still depends on manual and fragmented workflows. Data generation, analysis, and record keeping often rely on human effort. These processes slow innovation and create inconsistencies that make findings hard to reproduce. Preclinical labs spend enormous amounts of money and time repeating experiments, yet only a small fraction of published results can be replicated with confidence. The result is wasted resources and a loss of trust in biomedical research.
Against this backdrop, artificial intelligence stands out as a game changer. Life-science data is vast, multi-parameter, and complex. Gene expression profiles, protein networks, cell-to-cell interactions, tissue organization, whole-organ dynamics, and environmental influences all contribute to health and disease. No human team could synthesize this information at scale, but AI can integrate these layers and reveal patterns invisible to the eye.In imaging, AI has already transformed workflows, from super-resolution microscopy to pathology analysis. One of the most striking advances has been the ability of AI models to take blurry, low-resolution images of cells or tissues and reconstruct them with near-microscope clarity, saving both time and cost. In protein modeling, tools such as AlphaFold and newer diffusion-based models can now predict the three-dimensional structure of proteins with remarkable accuracy, something that once took years of lab work and millions of dollars. This leap is already reshaping how scientists approach drug discovery, enzyme design, and understanding disease mechanisms. In gene expression studies, AI systems are helping decode which genes are turned on or off under specific conditions, and are even starting to predict how changes in one pathway ripple through entire networks of cells. These capabilities would have been unthinkable only a decade ago, and they show why AI is often described as a “microscope for patterns”, not looking at cells directly, but revealing hidden structures in the data itself.
The promise is extraordinary, but the gap between research potential and real-world implementation remains wide. A major barrier is the data itself. Clinical datasets are among the most sensitive forms of information, raising deep privacy concerns whenever sharing is considered. Preclinical datasets are not private but are expensive to generate, so labs are cautious about releasing them. On top of this, the way data is stored and formatted is far from uniform. Each electronic medical record (EMR) system uses different structures and coding conventions, meaning that how “blood pressure” or “tumor size” is reported in one hospital database can be completely different in another. Imaging files add another layer of complexity: different devices, microscopes, cameras, and software all export data in their own formats. For AI to use these datasets, researchers must go through extensive cleaning and preprocessing steps, removing errors, normalizing formats, and aligning metadata, before the data is even ready to train a model. This hidden but crucial part of the workflow, often called “data wrangling,” can take far more time than the actual AI training.
Adding to this, interdisciplinary expertise, combining biology, medicine, data science, and ethics, is scarce. Without it, even the best tools risk being misapplied. AI can only be as good as the data and context it is given, which means that without careful stewardship, models may produce impressive results in controlled tests but fail in real-world scenarios.
Ethics and reproducibility compound these problems. Consent formats vary across institutions and countries, and many datasets collected in the past never anticipated AI applications, making retrospective use problematic. There are no unified guidelines for using published or online data in new contexts, leaving researchers unsure of what is permissible. Even leading AI developers face scrutiny over their training data sources. While some argue that fair use should apply, privacy remains a central concern. What is missing are user-friendly procedures that allow individuals to easily give or revoke consent for their data.
Digitization is another major obstacle. Many hospitals and research centers still rely on analog workflows. Pathologists use manual microscopes, medical records are stored as faxes or PDFs, and laboratory notes remain on paper. Powerful AI models already exist for pathology, but they cannot be deployed because many hospital microscopes do not produce digital scans. The technology to digitize processes is available, but adoption has been slow due to cost, lack of infrastructure, and limited incentives. Without digitization, AI will remain a laboratory tool rather than a clinical solution.
There are, however, clear paths forward. One idea is the development of consent platforms that let patients give, update, or withdraw permission for data use. With standardized protocols and transparent options, much of the “locked away” data in research centers could be ethically reactivated. Incentives, such as compensation or access to research results, could encourage participation.
On the technical side, federated learning provides a way to collaborate without moving sensitive data. Models are trained across institutions while the data stays local, reducing risk. Combined with approaches such as differential privacy or secure computation, this allows researchers to work with sensitive datasets while protecting individuals. At the same time, frameworks like the FAIR principles, which emphasize data being findable, accessible, interoperable, and reusable, can help ensure research outputs are more transparent and reproducible.
Reproducibility also needs to be built into AI workflows from the start. That means versioning datasets, documenting preprocessing steps, freezing code, and controlling for randomness. Just as importantly, it means close collaboration between domain experts and data scientists to ensure that models address biologically meaningful questions rather than spurious correlations.
Digitization must advance in parallel with AI. Tools such as augmented-reality microscopes, which overlay AI-generated insights onto what pathologists see in real time, could ease the transition from analog to digital. Companies and research groups are also helping labs digitize legacy data that would otherwise remain inaccessible. Without this step, the broader promise of AI will remain theoretical.
The future of AI in life sciences is not only about algorithms but about the infrastructure and culture around them. That includes standardized consent processes, stronger commitments to reproducibility, incentives for data sharing, and recognition of data stewardship alongside publications. Interdisciplinary collaboration will be essential, as will investment in digitization and ethical frameworks.
If these changes take hold, the vast volumes of unused biomedical data in silos could become engines of discovery rather than wasted assets. AI could finally move from pilot projects into everyday lab work and clinical decision-making. The scientific community could also begin to close the gap between what is published and what can actually be reproduced and applied for patient benefit.
AI has already proven its potential to transform life sciences. The next step is to create the systems, standards, and practices that will let it deliver on that promise responsibly and at scale. The sooner the community embraces this broader transformation, the faster discoveries that once seemed impossible will become routine.
About the Author
Negin Farivar, PhD
Co-founder & CTO, SnapCyte Solutions Inc.
Negin Farivar is the Co-founder and CTO of SnapCyte Solutions Inc., where she leads innovation in AI-driven real-time cell analysis. With a PhD in Experimental Medicine from The University of British Columbia, she brings deep expertise in advancing data standardization and accessibility in life sciences. At SnapCyte, Negin combines her passion for scientific innovation with a commitment to sustainability—driving eco-friendly solutions that accelerate research collaboration and scientific discovery.
